• The incidence and timing of locoregional recurrence, distant metastatic disease, new primary malignancies and death were evaluated retrospectively. (sagepub.com)
  • Incidence of distance metastatic disease and additional cancers were also studied.ResultsMedian follow-up from treatment initiation was 26·4 months (range 1·2-84·7 months). (sagepub.com)
  • There was an overall low incidence of distant metastatic disease (3·07%) and additional cancers (8·05%).ConclusionOverall and disease-free survival outcomes of a large cohort of HNC patients treated with definitive IMRT radiotherapy following treatment planning with PET-CT shows a similar high level of disease control and mortality rate as previously published outcome studies of shorter terms and/or smaller numbers of patients. (sagepub.com)
  • Exemestane is an aromatase inhibitor that blocks the conversion of androgens to estrogen and may be superior to tamoxifen in patients with metastatic disease. (aafp.org)
  • Prior chemotherapy for metastatic disease. (knowcancer.com)
  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. (drugs.com)
  • however, up to 30% of patients still relapse and die from metastatic disease. (curetoday.com)
  • Clinical and radiological followup showed no evidence of metastatic disease prior to the current presentation. (hindawi.com)
  • Drug-eluting beads trans-arterial chemoembolization for leiomyosarcoma, liver metastases from colorectal cancer, and for primary and liver-dominant metastatic disease of the liver. (aetna.com)
  • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (nih.gov)
  • CEST) - Patients with metastatic non-small cell lung cancer who received a combined therapy of tremelimumab, durvalumab and chemotherapy experienced longer overall survival compared with those who received chemotherapy alone, regardless of STK11, KEAP1 or KRAS mutational status, according to research from the POSEIDON trial presented at the IASLC World Conference on Lung Cancer 2022 in Vienna. (eurekalert.org)
  • In previously reported results of the phase 3 POSEIDON trial, patients with EGFR/ALK wild-type metastatic NSCLC who were given first-line tremelimumab, durvalumab and chemotherapy demonstrated statistically significant improvements in both progression-free survival and overall survival versus chemotherapy alone. (eurekalert.org)
  • Based on these findings, researchers theorized that the triplet regimen tremelimumab, durvalumab and chemotherapy may improve clinical outcomes for hard-to-treat subgroups of patients with metastatic NSCLC. (eurekalert.org)
  • The main outcomes included the overall and site-specific incidence, proportion of metastatic disease, overall survival (OS), and recurrence-free survival (RFS). (ices.on.ca)
  • AIM: To evaluate the clinical outcomes of laparoscopic resection of colorectal cancer in patients over 80 years old. (sages.org)
  • The availability of optimal cutoff(s) that might dichotomize the whole cohort into two groups with significantly different clinical outcomes was searched using receiver operating characteristic (ROC) curve analysis. (hindawi.com)
  • Background/aim: The aim of this study was to evaluate the clinical outcomes and identify the predictors of mortality in peritoneal dialysis patients. (tubitak.gov.tr)
  • Disease progression was observed in 9 patients (median progression-free survival 7.3 years). (nih.gov)
  • Median time until disease progression. (knowcancer.com)
  • The prognosis for pancreatic cancer (PAC) is one of the worst of any common solid tumor, with median and 5-year overall survival (OS) rates of only 12 months and 10%, respectively [ 1 - 3 ]. (hindawi.com)
  • Despite rigorous therapy, the estimated median survival time of such patients is only around 12 months [ 7 ], and 70% of all cases die as a result of extensive distant metastases (DM) [ 8 ]. (hindawi.com)
  • Results: During a median follow-up duration of 24 months, two patients died of disease progression, and 11 experienced recurrent tumors (eight intrathoracic tumors, two distant metastasis, and one both types of recurrences). (iiarjournals.org)
  • Median age was 64 years, PS 0 (69%) or 1 (31%), 63% patients had cirrhosis, 29% portal vein thrombosis and 70% extra-hepatic disease. (nature.com)
  • The five- and ten-year central neck recurrence-free probability was 98.4 percent in the non-PCND group and 93.6 percent in the PCND group (p = 0.133), with a median follow-up of 65 months. (mskcc.org)
  • Median overall survival was 20 months (95% CI 15-25 months) for patients with pCCA and 17 months (95% CI 11-23 months) for patients with GBC (p = 0.135). (bvsalud.org)
  • Patients with GBC had significantly shorter median disease-free survival (DFS), 10 months (95% CI 3-17 months) compared 17 months (95% CI 15-19 months) for patients with pCCA (p = 0.010). (bvsalud.org)
  • OS is a secondary outcome and QoL is not tracked. (medscape.com)
  • OS over 4 years is a secondary outcome. (medscape.com)
  • Secondary outcomes included disease-free survival, pathological response (in the neoadjuvant setting only), adverse events, treatment adherence and quality of life. (mendeley.com)
  • Secondary outcome measures include operative time, blood loss, complication rates, hospital stay, and time to tolerate fluid diet. (sages.org)
  • Primary and secondary endpoints were the potential association between the post-CCRT NLR measures and distant metastasis-free survival (DMFS) and overall survival (OS) outcomes. (hindawi.com)
  • The primary outcome of the STEM-PD trial is to assess safety and tolerability of the transplanted product at 1-year post-transplantation, while secondary endpoints will assess survival and function of the transplanted cells by brain imaging, as well as measure effects on Parkinson's symptoms. (lu.se)
  • This study aimed to retrospectively evaluate the overall survival and disease-free survival outcomes of patients with HNC who received definitive IMRT with or without chemotherapy, planned with PET-CT.Materials and MethodsA total of 1,200 patients underwent treatment for HNC during the study period, from 1 January 2002 to 31 December 2010. (sagepub.com)
  • Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer. (curetoday.com)
  • Platinum-based chemotherapy, given before chemoradiation, improved outcomes for patients with advanced cervical cancer. (curetoday.com)
  • Patients with locally advanced cervical cancer saw an improvement in survival when they added platinum-based chemotherapy before chemoradiation, compared to those who had chemoradiation alone, according to findings from the phase 3 INTERLACE clinical trial. (curetoday.com)
  • Treatment with ATRA and anthracycline-based chemotherapy (ATRA + chemotherapy) decreases relapses of the disease as well as early hemorrhagic deaths. (druglib.com)
  • However, there is no report comparing treatment outcomes of "ATO + ATRA + chemotherapy" and "RIF + ATRA + chemotherapy" protocols in children with APL so far. (druglib.com)
  • Overall survival hazard ratios favored patients in the tremelimumab, durvalumab and chemotherapy arm versus chemotherapy, irrespective of KRAS, STK11 or KEAP1 mutational status, consistent with results in the intent-to-treat population. (eurekalert.org)
  • Notably, landmark 24-month overall survival rates were higher with tremelimumab, durvalumab and chemotherapy versus chemotherapy across all subgroups, including those with KRASm, STK11m and KEAP1m, suggesting sustained benefit with the triplet regimen," Dr. Peters reported. (eurekalert.org)
  • A Phase III study, which utilized the BSD-2000 Hyperthermia System, demonstrated that patients with high risk soft-tissue sarcomas were 30% more likely to be alive and cancer free almost three years after starting treatment if targeted heat therapy (hyperthermia) was added to their chemotherapy treatment. (news-medical.net)
  • The press information stated that, "The study, which found that the addition of the innovative heat technique more than doubled the proportion of patients whose tumours responded to chemotherapy without increasing toxicity, is also the first to show that any treatment other than surgery followed by radiation can prolong survival of this type of patient. (news-medical.net)
  • Almost three years after starting treatment, they were 42% less likely to experience a recurrence of their cancer at the same site or to die than those who were getting chemotherapy alone, surviving an estimated 120 months before local progression of their disease, compared with an estimated 75 months. (news-medical.net)
  • Breast cancer patients are typically offered surgery and chemotherapy or radiation treatment before taking hormone blocking drugs to try to stop the disease recurring. (yahoo.com)
  • Newer studies with intensive multiagent chemotherapy (eg, the CALGB [Cancer and Leukemia Group B]- 8811 and hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone] regimens and the ALL-2 regimen) plus the addition of TKIs for Ph+ ALL and rituximab for CD20-positive ALL have resulted in 3-y survivals of 50% or more in adults. (medscape.com)
  • In this study, we analysed the effect of administration and timing of systemic chemotherapy on the outcome of lymph node positive colorectal carcinoma patients treated with CRS-HIPEC. (lu.se)
  • Different chemotherapy timings did not differ significantly in either survival or recurrence patterns. (lu.se)
  • Factors to consider if contemplating chemotherapy include stage of disease, general medical status, potential efficacy, and tolerance to adverse effects. (medscape.com)
  • Clinic pathologic characteristics and outcomes in the 1,802 patients from the three treatment groups included in the analysis (601 in control group, 650 in sequential trastuzumab group, and 551 in concurrent trastuzumab group) were similar to excluded patients in the three treatment groups. (ascopost.com)
  • We retrospectively reviewed the clinicopathological characteristics and survival outcomes. (sages.org)
  • In addition to tumor characteristics, low income and rural residency portend worse survival for patients with NETs. (ices.on.ca)
  • We reviewed the PTCA literature from 1978-93 for long-term outcome (cardiac events) and patient characteristics that might affect outcome. (nih.gov)
  • Objectives To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy. (mendeley.com)
  • It is also important to point out that the International Classifications of Diseases for Oncology (ICD-O) assigns a benign behavioral code "/1" that corresponds to neoplasia of uncertain and unknown behavior. (medscape.com)
  • Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes (cN1b disease) may not require prophylactic central compartment neck dissection (PCND), according to our retrospective study published recently in the Annals of Surgical Oncology . (mskcc.org)
  • NK cell infiltration into tumor tissue is associated with better disease prognosis in colorectal cancer, clear cell renal cell carcinoma, and lung carcinomas ( 9 - 11 ). (frontiersin.org)
  • In Kaplan-Meier-Analysis, the poorest event-free survival was observed among patients with CRS. (uzh.ch)
  • 1. Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. (cancercentrum.se)
  • No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study. (cancercentrum.se)
  • Fertillity-sparing surgery for treatment of non-epithelial ovarian cance: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study. (cancercentrum.se)
  • In this review we will discuss various treatment options available in management of colorectal liver metastases with potential guidance on how and when to choose these options along with consideration on future directions in management of this disease. (wjgnet.com)
  • TNBCs are associated with high recurrence rates, rapid metastases, poor survival, and in- creased mortality compared with other histologic breast cancer subtypes. (bvsalud.org)
  • Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a SweGCG study. (cancercentrum.se)
  • Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. (cancercentrum.se)
  • For time-to-event outcomes of overall survival and disease-free survival, we derived hazard ratios (HRs) with 95% confidence intervals (CI) where possible. (mendeley.com)
  • There were no significant differences in disease-free survival between patients with PTEN-positive vs PTEN-negative tumors defined as IHC 0 staining among all patients (hazard ratio [HR] = 0.96, P = .70) or within the control (HR = 0.92, P = .64), sequential trastuzumab (HR = 0.81, P = .27), or concurrent trastuzumab (HR = 1.40, P = .20) groups. (ascopost.com)
  • Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival. (cdc.gov)
  • The studies needed to have reported on at least one of our outcomes of interest, which included overall survival, disease-free survival, pathological response, treatment adherence, toxicity and quality of life. (mendeley.com)
  • For dichotomous outcomes of pathological complete response, treatment adherence and adverse events, we reported the treatment effect as a risk ratio (RR) with 95% CI where possible. (mendeley.com)
  • Efficacy was evaluated by pathological complete response (pCR), minimal residual disease (MRD), and 3-year biochemical progression-free survival (bPFS). (frontiersin.org)
  • Compared with ADT alone, neoadjuvant therapy with ADT plus docetaxel or abiraterone could achieve better pathological outcomes (pCR or MRD) for very-high-risk localized prostate cancer. (frontiersin.org)
  • Background: There are few population-based data on the disease burden of cervical cancer from developing countries, especially South Pacific islands. (researchgate.net)
  • We present long-term clinical and oncological outcomes of maximal safe resection. (nih.gov)
  • Paediatric patients with low-grade thalamopeduncular gliomas have excellent long-term functional and oncological outcomes when gross total resection is not achievable. (nih.gov)
  • A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women. (cancercentrum.se)
  • Centers for Disease Control and Prevention. (cdc.gov)
  • Specifically, CDPH is enhancing their system to better capture parent-child elements and ensure that the data collected can be accessed seamlessly by the U.S. Centers for Disease Control and Prevention. (cdc.gov)
  • AHCA data contain medical records on all patients treated at hospitals and free-standing surgical and radiological treatment centers (6). (cdc.gov)
  • Exemestane improves outcomes for postmenopausal women with estrogen-receptor-positive breast cancer when given for two to three years after a two- to three-year course of treatment with tamoxifen. (aafp.org)
  • Patients with positive lymph node status have worse survival after CRS-HIPEC, which is probably due to higher rates of systemic failure. (lu.se)
  • Patient must have radiologically measurable disease (RECIST 1.1), as confirmed by imaging within the 28 days prior to randomization. (who.int)
  • Patients with duodenal GIST who underwent complete surgical resection have favorable survival outcomes. (sages.org)
  • Prognosis depends on the age of onset of symptoms with a better prognosis being associated with later onset disease. (wikipedia.org)
  • Aggressive breast cancer is a highly heterogeneous disease caused by a variety of distinct cell-intrinsic genetic alterations in mammary epithelial cells, leading to vastly heterogenic disease manifestation in individual patients and predominantly affecting patient prognosis and treatment options [ 14 ]. (nature.com)
  • The 2016 World Health Organization (WHO) classification of lymphoid neoplasms incorporates genetic data, clinical features, cell morphology, and immunophenotype, all of which have important implications for disease prognosis and management. (msdmanuals.com)
  • While localized melanoma has an excellent prognosis, regional and distant disease is associated with much poorer outcomes. (medscape.com)
  • Outcomes such as rate of amputation, pain, amputation-free survival and adverse effects were not assessed. (cochrane.org)
  • Patents receiving trastuzumab had significantly better disease-free survival and overall survival compared with the control group, and patients receiving concurrent trastuzumab had significantly better disease-free survival than those receiving sequential trastuzumab. (ascopost.com)
  • Trial results show it can boost survival and significantly slash the chances of cancer coming back. (yahoo.com)
  • Researchers found that when combined with hormone therapy, ribociclib significantly reduced the chances of the disease returning in women with oestrogen receptor-positive, HER2-negative primary breast cancer. (yahoo.com)
  • The STEM-PD trial is investigating the safety and tolerability of transplanting STEM-PD cells into the brain of patients with moderate Parkinson's disease (EudraCT Number:2021-001366-38). (lu.se)
  • https://coloncancerfoundation.org/wp-content/uploads/2022/10/jzyhmzuvur474dyzuiga.jpg 389 600 [email protected] https://coloncancerfoundation.org/wp-content/uploads/2017/01/CCCF_Logo_Final_Color.png [email protected] 2023-10-24 09:36:52 2023-10-24 09:36:52 Disease-Free Survival: How Does Exercising Impact Colon Cancer? (coloncancerfoundation.org)
  • But in the new study, researchers discovered it may also boost outcomes for patients with much earlier-stage disease, including those with cancer that has not yet spread to the lymph nodes. (yahoo.com)
  • The remaining trials were either underpowered, at high or unclear risk of bias, inadequately reported, of short duration or measured surrogate outcomes of unproven relationship to mortality or disease progression, which precluded any benefits reported being reliable. (springer.com)
  • Given the limited evidence supporting these endorsements, we examined outcomes for 152 patients who underwent surgery for well-differentiated thyroid carcinoma at Memorial Sloan Kettering Cancer Center (MSK) from 1986 to 2015. (mskcc.org)
  • Overall and disease-free survival (survival to time of first recurrence) were determined by the life table method. (sagepub.com)
  • Refers to a disease or condition that persists, often slowly, over a long time. (cancer.net)
  • However, limited research has documented associations among Native American race, use of IHS, and survival time after cancer diagnosis (4). (cdc.gov)
  • The primary outcome of our study, overall survival, was elapsed time from diagnosis to date of death or last patient encounter. (cdc.gov)
  • We excluded non-Florida residents aged 18 years or younger, patients with missing values for survival time, and patients with carcinoma in situ. (cdc.gov)
  • however, neurological function should not be endangered due to excellent chance for long-term survival. (nih.gov)
  • LR is feasible and effective surgical treatment for the patients with small-sized, and anti-mesenteric sided duodenal GIST in terms of long-term oncologic outcomes and quality of life. (sages.org)
  • Given the long-term, although potentially fatal, nature of prostate cancer, there is increasing observational evidence for the reduction in disease progression and mortality through changes in lifestyle factors. (springer.com)
  • Given the long-term chronic, but potentially fatal, nature of the disease, there is growing interest in low-toxicity interventions in the tertiary prevention of morbidity and mortality due to prostate cancer. (springer.com)
  • This conundrum brings to question whether cancer ST6GAL1 overexpression is beneficial or ultimately detrimental to long-term patient outcomes and highlights the incomplete mechanistic understanding of how ST6GAL1 is involved in cancer progression. (nature.com)
  • Access to transplantation entails more than the surgery itself, because success is measured by longer survival of the patient and a long-term improvement in the quality of life. (who.int)
  • After three years, 90.4% of those taking ribociclib remained free of disease, compared with 87.1% in the hormonal therapy alone group. (yahoo.com)
  • Peutz-Jeghers syndrome has periorificial freckling along with hamartomatous intestinal polyps, and, as a differential diagnosis, Laugier-Hunziker syndrome presents with macular mucocutaneous hyperpigmentation and melanonychia with no known systemic disease association. (medscape.com)
  • Approximately 30% of all PAC patients have nonmetastatic but locally advanced unresectable disease, namely, locally advanced pancreatic cancers (LAPAC) [ 4 , 5 ]. (hindawi.com)
  • A total of 132 (96.4%) participants had very-high-risk prostate cancer, and 108 (78.8%) had locally advanced disease. (frontiersin.org)
  • Overall survival (OS) and quality of life (QoL) are the primary outcome measures. (medscape.com)
  • For example, in developing and developed countries alike, kidney transplantation not only yields survival rates and quality-of-life that are far superior to those obtained with other treatments for end-stage renal disease, such as haemodialysis, but is also less costly in the long run. (who.int)
  • GSD-II and Danon disease are the only glycogen storage diseases with a defect in lysosomal metabolism, and Pompe disease was the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe. (wikipedia.org)
  • Aims: Fabry disease (FD) is a rare X-linked lysosomal storage disease with a deficiency of α-galactosidase A leading to progressive sphingolipid accumulation in different organs, among them heart and kidney. (uzh.ch)
  • However, delay in providing therapy to patients with urinary antigen tests with negative results did not influence outcome. (cdc.gov)
  • RESULTS: There is no statistical significant difference in 30-days mortality, overall and disease-free survival between 2 groups. (sages.org)
  • The results showed a decrease in ulcer size and improvement in pain-free walking distance in the group receiving the stem cell implantation compared with the group receiving placebo and standard wound dressing care. (cochrane.org)
  • Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. (qxmd.com)
  • 50%), disease stage (IVA vs IVB), and histology (squamous vs non-squamous). (eurekalert.org)
  • To our knowledge, this disease-free interval is the longest among previous reports of pulmonary metastasis of uterine leiomyosarcoma. (hindawi.com)
  • Although doxorubicin was initially considered the agent of choice in advanced HCC, two controlled trials suggested it is associated with poor survival and a modest overall response rate compared with the best supportive care. (nature.com)